bezafibrate / Generic mfg. - LARVOL DELTA

Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study. (PubMed, Am J Gastroenterol) - "In this real-world nationwide study, the one-year fibrate discontinuation rate was substantial. However off-label use of bezafibrate was associated with reductions in the biochemical markers of cholestasis in PBC, which were associated with clinical outcome in this setting of second line therapy."

Journal • Real-world evidence • Cholestasis • Hepatology • Immunology • Liver Failure • Primary Biliary Cholangitis • Transplantation

Development of a methodology in an automated system for analysis of naproxen and bezafibrate in in-situ formation using a deep eutectic solvent by liquid chromatography. (PubMed, J Chromatogr A) - "The precision results were lower than 15.9% and recoveries ranged from 71 to 102%. The greenness of the methodology was confirmed using the AGREEprep tool, demonstrating that the proposed strategy offers a sustainable, selective, and high-throughput alternative for the determination of emerging pharmaceutical contaminants in aquatic environments."

Journal

mLeveraging genetic correlations to prioritize drug groups for repurposing in type 2 diabetes. (PubMed, Pharmacogenomics J) - "Notably, bezafibrate, a PPAR pan-agonist, demonstrated substantial genetic overlap with T2D loci, supporting its potential in metabolic disease. This study introduces a genetically informed pipeline for drug repurposing based on multi-trait gene set analysis."

Journal • Diabetes • Metabolic Disorders • Oncology • Type 2 Diabetes Mellitus • KCNQ1OT1 • PPARG

Targeting PRDM1 to Enhance CAR T Cell Therapy Against Diffuse Large B Cell Lymphoma (DLBCL) (ASH 2024) - "From a translational perspective, we assessed the potential synergistic effects of a PGC1α agonist, bezafibrate, with CAR T cells...Building upon a correlation between PRDM1 expression and CAR T cell dysfunction, we aim to pioneer the use of PRDM1 and/or its target genes as novel biomarkers for predicting clinical responses of r/r DLBCL patients to CAR T cell therapy. Our endeavors will better elucidate the mechanisms by which PRDM1 determines the fates of clinical CAR T cell products and the translational potential of targeting PRDM1/PRDM1-mediated pathways to generalize the application of CAR T cell therapy against cancers."

CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD8 • PPARGC1A • PRDM1

Incidence and Prevalence of Primary Biliary Cholangitis (PBC) and Cholestatic Pruritus (CP) in Germany: Results From a Statutory Health Insurance (SHI) Claims Analysis (ISPOR-EU 2025) - "Pruritus is a common symptom in PBC, especially in female patients. However, treatment patterns in Germany show decreasing reliance on cholestyramine, with increasing use of alternative therapies."

Reimbursement • US reimbursement • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - No abstract available

Oxidative stress • Preclinical • Inflammation

Bezafibrate prevents myelin alterations, neuroinflammation, and oxidative stress induced by sulfite intrastriatal administration in rats (SSIEM 2023) - "Sulfite administration decreased Fluoromyelin and myelin basic protein staining, indicating myelin alterations. Sulfite also increased the staining of NG2, a protein marker of oligodendrocyte progenitor cells, suggesting the induction of remyelination. In line with these findings, sulfite also reduced the viability of MO3.13 cells, a cell line with oligodendroglial characteristics."

Oxidative stress • Preclinical • CNS Disorders • Epilepsy • Genetic Disorders • Inflammation • Solid Tumor • HMOX1 • IL10 • IL1B • IL6 • MBP

Investigating antidiabetic drug targets as potential therapeutic modulators for schizophrenia. (PubMed, Psychopharmacology (Berl)) - "Antidiabetic drugs may possess therapeutic potential in schizophrenia by modulating specific drug-related pathways.These findings provide new theoretical support for the selection of ADs in patients with schizophrenia comorbid with diabetes, and also offer new insights for the future development of APs."

Journal • CNS Disorders • Diabetes • Metabolic Disorders • Psychiatry • Schizophrenia • KCNJ11 • RXRB

Bezafibrate, a Pan PPAR agonist, attenuates experimental rheumatoid arthritis via PPAR dependent modulation of inflammatory pathways with emphasis on PPAR γ activity. (PubMed, Int Immunopharmacol) - "Initially, molecular docking was performed using a panel of fibrate-class compounds (including pemafibrate, bezafibrate, fenofibrate, gemfibrozil, and clofibrate) against the ligand-binding domain of PPAR-γ (PDB ID: 7WGO). These findings suggest that bezafibrate, selected through integrative computational and pharmacological screening, effectively ameliorates experimental autoimmune arthritis via PPAR-γ activation. This highlights its promise as a repurposed therapeutic candidate and warrants further investigation."

Journal • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • IL1B • IL6 • TNFA

A dispersion-corrected DFT calculation on the drug delivery of Bezafibrate using pectin biopolymer. (PubMed, Sci Rep) - "Additionally, the recovery time was estimated to analyze the interaction mechanism between the bezafibrate drug and pectin, as well as its effect on drug release. These insights contribute to the understanding of Pectin's polysaccharides in biomedical applications, particularly for advanced drug delivery systems."

Journal

Novel Drug Molecules for Atherosclerosis from Ginkgo biloba, an Endangered Himalayan Herb, Via Pharmacoinformatics Approaches. (PubMed, Curr Pharm Biotechnol) - "The findings highlight the multi-target therapeutic potential of Isoginkgetin in mitigating the initiation and progression of atherosclerosis."

Journal • Atherosclerosis • Cardiovascular • Inflammation • Metabolic Disorders • CYP19A1 • PACERR • PTGS2

Fibrates as an Adjunct Therapy in Primary Biliary Cholangitis: A Propensity-Matched Analysis of Major Adverse Cardiovascular Events (ACG 2025) - "Cohort A was also prescribed an additional fibrate (fenofibrate, gemfibrozil, bezafibrate, or ciprofibrate); Cohort B received UDCA monotherapy. The fibrate cohort had higher baseline total cholesterol (212.7 ± 90.0 vs 191.5 ± 66.7 mg/dL, p 0.05). Over a five-year period, fibrate and UCDA-only patients did not differ in the incidence of MACE (HR 1.09, 0.91-1.29, p = 0.35), no individual MACE components (all p-values > 0.05) , or all-cause mortality (HR 0.92, 0.73-1.16, p = 0.47). In this large U.S. real-world cohort, adding a fibrate to UDCA did not significantly increase MACE or mortality despite a more atherogenic lipid profile at baseline. The modest, nonsignificant excess in event rates likely reflects residual confounding from patients selected for fibrate therapy because of dyslipidemia."

Adverse events • Cardiovascular • CNS Disorders • Congestive Heart Failure • Coronary Artery Disease • Diabetes • Dyslipidemia • Heart Failure • Hepatology • Hypertension • Immunology • Metabolic Disorders • Myocardial Infarction • Primary Biliary Cholangitis

Fibrates as an Adjunct Therapy in Primary Biliary Cholangitis Is Associated With Lower Hospitalization and Healthcare Utilization: A Propensity-Matched Analysis (ACG 2025) - "Introduction: Fibrates is considered a second line agent for primary biliary cholangitis (PBC) and improves biochemical responses in PBC patients not responding to ursodeoxycholic acid (UDCA)...Cohort A was also prescribed additional fibrate (fenofibrate, gemfibrozil, bezafibrate, or ciprofibrate); Cohort B was on UDCA monotherapy... Over five years, fibrate patients were less likely to develop spontaneous bacterial peritonitis (2.0 % vs. 1.1%, HR 0.52, 0.29-0.92), and had fewer incidences of all-cause hospitalizations ( 26.7 % vs. 21.8%, HR 0.75, 0.65-0.86)."

Clinical • HEOR • CNS Disorders • Fatigue • Fibrosis • Hepatic Encephalopathy • Hepatocellular Cancer • Hepatology • Immunology • Musculoskeletal Diseases • Osteoporosis • Primary Biliary Cholangitis • Rheumatology • Solid Tumor

Metabolic flux analysis of bile acid biosynthesis acidic pathway in HepG2 cells reveals CYP8B1 inhibition of azole antifungals. (PubMed, Drug Metab Dispos) - "To address the challenge of cellular CYP8B1 inhibition characterization, this work developed a pharmacologically optimized HepG2 cells model using triiodothyronine-dexamethasone-bezafibrate (TDB) induction, which significantly enhances the 12α-hydroxylation activity along the acidic pathway of BA biosynthesis in HepG2 cells...Econazole acted as a relatively selective CYP8B1 inhibitor with a cellular half-maximal inhibitory concentration of 0.31-0.45 μM, tioconazole and posaconazole dually inhibited CYP8B1 and sterol 27-hydroxylase (CYP27A1), itraconazole and voriconazole primarily inhibited CYP27A1, and fluconazole showed no activity toward either enzyme. This study provides the first direct evidence that CYP8B1 participates in cholic acid synthesis via the acidic pathway and establishes a high-throughput cellular platform for screening CYP8B1 inhibitors, revealing azoles as effective modulators of this pathway. SIGNIFICANCE STATEMENT: Optimized HepG2 model using a..."

Journal • Metabolic Disorders • APOA1 • CYP27A1 • CYP8B1

Investigating the Mechanisms of Mitochondrial Dysfunction in Ischemic Stroke and Predicting Therapeutics Through Machine Learning and Integrated Bioinformatics. (PubMed, Curr Med Chem) - "Our findings underscore mitochondrial dysfunction not only as a critical factor in IS pathogenesis but also as a viable therapeutic target. The identified MRG signature presents potential for clinical application in diagnostic and pharmacological strategies aimed at ameliorating ischemic injury. This study highlights the translational significance of systems biology approaches within cerebrovascular medicine, warranting further mechanistic exploration of mitochondrial-immune interactions in stroke pathology."

Journal • Cardiovascular • CNS Disorders • Ischemic stroke • Metabolic Disorders • Vascular Neurology • ACSL1 • ALDH2 • CD8 • PDK4

COMPARATIVE EFFECTIVENESS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR AGONISTS AS SECOND-LINE THERAPIES FOR PRIMARY BILIARY CHOLANGITIS: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (AASLD 2025) - "For patients with inadequate response or intolerance to ursodeoxycholic acid (UDCA), peroxisome proliferator-activated receptor (PPAR) agonists have emerged as promising second-line therapies...A sensitivity analysis for the primary outcome including obeticholic acid (OCA) was also performed. Eight RCTs comprising 727 participants and four PPAR agonists (bezafibrate, seladelpar, elafibranor and saroglitazar) were included... Add-on PPAR agonists are effective second-line therapies in PBC, bridging an important treatment gap. Treatment ranking variability may reflect heterogeneity in patient populations and drug mechanisms. In the absence of head-to-head trials, NMA provides valuable comparative insights; however, long-term safety data and patient-centered outcomes remain priorities for future studies."

HEOR • Retrospective data • Review • Cholestasis • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Primary Biliary Cholangitis

NON-RESPONSE TO OBETICHOIC ACID IS ASSOCIATED WITH HEIGHTENED RISKS OF DEVELOPING CLINICAL EVENTS IN PRIMARY BILIARY CHOLANGITIS (AASLD 2025) - "Background: Biochemical non-response to ursodeoxycholic acid (UDCA), as a first-line therapy, is associated with a heightened risk of clinical events in primary biliary cholangitis (PBC). Herein, we determine whether biochemical non-response to obeticholic acid (OCA) is also predictive of long-term event-free survival. A further, exploratory objective was to evaluate whether responses differ between combination OCA + fibric acid derivative therapy compared to switching from OCA to bezafibrate/fenofibrate... Biochemical response stratifies risk of clinical events under OCA treatment. Whilst response rates increase over time, discontinuation rates underscore need for newer treatment paradigms, including combination therapy with fibric acid derivatives."

Clinical • Fibrosis • Hematological Disorders • Hepatocellular Cancer • Hepatology • Immunology • Primary Biliary Cholangitis • Solid Tumor • Thrombocytopenia

An update on novel investigational agents for the treatment of primary biliary cholangitis. (PubMed, Expert Opin Investig Drugs) - "While ursodeoxycholic acid (UDCA) remains the first-line treatment, up to 40% of patients show an inadequate response...Obeticholic acid (OCA), a farnesoid X receptor agonist, was initially approved but recently lost its marketing authorization in the EU due to an unfavorable risk-benefit balance. Fibrates, particularly bezafibrate and fenofibrate, have shown promising results in improving biochemical markers and reducing pruritus, although they remain off-label. We here focus on new FDA- and EMA-approved therapies, including the PPAR agonists elafibranor and seladelpar, which demonstrate improved biochemical response and, in the case of seladelpar, a significant reduction in pruritus. Additional investigational agents include NOX inhibitors such as setanaxib, IBAT inhibitors like linerixibat and odevixibat, and golexanolone, targeting fatigue through modulation of GABAergic neurotransmission. Despite advances, challenges remain in treatment personalization, access to..."

Journal • Review • Dermatology • Fatigue • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Liver Failure • Primary Biliary Cholangitis • Pruritus

Dual activation of PPARα/γ by bezafibrate triggers PINK1/Parkin-Mediated mitophagy to enhance lenvatinib sensitivity in hepatocellular carcinoma. (PubMed, Biochem Pharmacol) - "This approach demonstrated efficacy, inducing PINK1/Parklin-mediated mitophagy and reducing VEGF-A/C and EGFR in vitro, and decreasing tumor volume and weight in a syngeneic H22 mouse model compared to lenvatinib alone, without significant toxicity. In conclusion, bezafibrate, through PPARα/γ-mediated PINK1/Parkin activation and angiogenic suppression, complements lenvatinib's therapeutic effects in HCC, providing a rationale for clinical evaluation to address treatment resistance."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • ACOX1 • ANXA5 • CPT1A • EGFR • PPARA • PPARG

Bezafibrate for severe refractory intrahepatic cholestasis of pregnancy: a case report and literature review. (PubMed, BMC Pregnancy Childbirth) - "This case highlights a rare, severe, and treatment-refractory presentation of ICP. The marked improvement following bezafibrate supports its potential as a therapeutic consideration in similar high-risk cases. Further research is needed to evaluate its safety and efficacy in pregnancy."

Journal • Cholestasis • Dermatology • Hepatology • Pruritus

Pruritus in primary biliary cholangitis: insights from the German PBC registry across secondary and tertiary care. (PubMed, Ann Hepatol) - "Pruritus in patients with PBC is common and under-treated in the real-world scenario. Assessment and management vary by healthcare level, highlighting the need for standardized care and greater awareness of treatment options across all settings."

Journal • Dermatology • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

META-ANALYSIS OF THE EFFICACY AND SAFETY OF NOVEL ORAL ANTI-CHOLESTATIC AGENTS FOR PRIMARY BILIARY CHOLANGITIS (UEGW 2025) - "While ursodeoxycholic acid (UDCA) is the first-line therapy, about 40% of patients have incomplete responses, necessitating alternative treatments...Investigated therapies included seladelpar, fenofibrate, saroglitazar, bezafibrate, elafibranor, and budesonide... Novel oral anti-cholestatic agents show promise in managing PBC patients with suboptimal UDCA responses, demonstrating significant improvements in biochemical markers and some symptomatic relief. However, study heterogeneity, small sample sizes, and limited follow-up durations restrict direct comparisons and generalizability. Further research is needed to confirm long-term efficacy and safety."

Retrospective data • Cholestasis • Dermatology • Fatigue • Hepatology • Immunology • Primary Biliary Cholangitis • Pruritus

REPURPOSING MITOCHONDRIA PROTECTIVE TARGETS FOR ADJUVANT THERAPY IN INFLAMMATORY BOWEL DISEASES (UEGW 2025) - "Aims & Cellular toxicity of the drugs Acipimox, AICAR, ALCAR, Bezafibrate, Epi-743, Idebenone, Metformin, SS-31 and TUDCA was assessed in the intestinal epithelial cell line Mode-K and murine wild-type (WT) small intestinal (SI) organoids. Selected drugs targeting mitochondrial functions restored seeding efficiency, differentiation, and stemness of intestinal organoids from inflamed tissue sections of TNFΔARE mice, TNFΔARE pigs, and CD patients. These findings clearly support the potential of metabolic drug repurposing for adjuvant IBD therapy and indicate putative risks for Metformin."

Clinical • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Metabolic Disorders • IL10